Tag Archives: ACA

BIO Urges States to Use CMS Grants to Combat Discrimination by Health Plans

new-bio-logo

On June 15, the Centers for Medicare and Medicaid Services (CMS) announced $22 million in Affordable Care Act (ACA) funding for state insurance departments.  The Agency’s announcement noted that States are meant to utilize the funding to ensure that plans comply with “key consumer protections,” listing among them: essential health benefits, preventive services, parity in mental health and substance use disorder benefits, appeals processes, and bringing down the cost of health care coverage (also known Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

NYTimes Reports Insurers are Struggling, Their Own Data Says Otherwise

health care, medicine

The New York Times’ Reed Abelson yesterday reported on the plight of insurers who are supposedly losing money thanks to the Affordable Care Act (ACA) and asks the existential question: “Can insurance companies run a viable business in the individual market?” In short, yes. More broadly, most insurers are not just “viable.” They are thriving. Despite what insurance companies may say in print, the financial data paints a different picture. In the age of the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Exchange Plans are Helping Patients, But Challenges Remain

Session

After describing many of the benefits the Exchanges have brought to patients—including access to both coverage and federal subsidies—the moderator for the 2014 BIO International Convention breakout session, Impact of Exchanges for Patients, tasked panelists representing a diverse group of stakeholders to describe the challenges that remain for patients enrolled in Exchange plans. These challenges fell into four main categories, including: formulary depth, patient out-of-pocket costs, transparency, and provider networks. In terms of formulary depth, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Business Roundtable: The Reimbursement Landscape under ACA

Capture

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one of the most pressing issues facing healthcare stakeholders and decision makers, including patients, payers, providers, and innovative drug developers. BIO hosted a business roundtable discussion on this timely topic yesterday at our 16th Annual BIO CEO & Investor Conference. Moderated by Real Endpoint’s Roger Longman, panelists represented a variety of perspectives: Peter Bach, MD, MAPP, Attending Physician, Memorial Sloan-Kettering Cancer Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The Affordable Care Act is Here to Stay

The Affordable Care Act is Here to Stay

The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes, however, will impact the biotechnology industry and the future of patient access to needed medicines. In an expert panel at the 2013 BIO International Convention moderated by BioCentury’s Steve Usdin, multiple stakeholders addressed key elements of the ACA focused on both the value the ACA Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,